Begin main content

CADTH pan-Canadian Oncology Drug Review

pCODR RSS feed

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Cabozantinib (Cabometyx) for Hepatocellular Carcinoma
(Open for Input on Submission until October 30, 2019)

Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer
(Open for Input on Submission until October 29, 2019)

Brentuximab Vedotin (Adcetris) for Peripheral T-Cell Lymphoma
(Open for Input on Submission until October 23, 2019)

Atezolizumab (Tecentriq) Advanced or Metastatic Triple-Negative Breast Cancer
(Open for Input on Submission until October 17, 2019)

Atezolizumab (Tecentriq) for Small Cell Lung Cancer
(Open for Input on Recommendation until October 18, 2019)

Olaparib (Lynparza) for Newly Diagnosed Ovarian Cancer
(Open for Input on Recommendation until October 18, 2019)

Neratinib (Nerlynx) for Hormone Receptor-Positive Breast Cancer
(Open for Input on Recommendation until October 18, 2019)

Pembrolizumab for Metastatic Urothelial Carcinoma
(Final Recommendation Issued as of October 3, 2019)

Gilteritinib (Xospata) for Acute Myeloid Leukemia 
(Pending Submission as of September 27, 2019)

Find a Drug Review